BriaCell Therapeutics Announces Closing of $15 million Public Offering
Rhea-AI Summary
BriaCell Therapeutics (NASDAQ: BCTX), a clinical-stage biotechnology company focused on immunotherapy for cancer care, has successfully closed a $15 million public offering. The offering consisted of 12 million units priced at $1.25 per unit, with each unit comprising one common share (or pre-funded warrant) and one warrant.
The warrants are exercisable at $1.50 per share for a five-year period, while pre-funded warrants have an exercise price of $0.001. ThinkEquity served as the sole placement agent. The company plans to utilize the proceeds for working capital, general corporate purposes, and advancing its business objectives.
Positive
- Successfully raised $15 million in gross proceeds through public offering
- Five-year warrant term provides long-term funding flexibility
- Strengthened capital position for advancing business objectives and working capital
Negative
- Potential dilution for existing shareholders
- Offering price of $1.25 per unit may represent a discount to market price
- Additional warrants could lead to future dilution if exercised
News Market Reaction – BCTX
On the day this news was published, BCTX gained 1.13%, reflecting a mild positive market reaction. Argus tracked a peak move of +4.9% during that session. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $64K to the company's valuation, bringing the market cap to $6M at that time.
Data tracked by StockTitan Argus on the day of publication.
PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its best-efforts public offering of 12,000,000 units. Each unit consists of one common share (or one pre-funded warrant (“Pre-Funded Warrant”) in lieu thereof) and one warrant (the “Warrants”). Each unit was sold to the public at a price of
No Canadian prospectus has been or will be filed in a province or territory of Canada to qualify the securities in connection with the offering. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.
The Company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives.
ThinkEquity acted as the sole placement agent for the offering.
A registration statement on Form S-1 (File No. 333-288562) relating to the securities was filed with the Securities and Exchange Commission (“SEC”) and became effective on July 15, 2025. This offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. The final prospectus has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About BriaCell Therapeutics
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Forward Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
FAQ
How much did BriaCell Therapeutics (BCTX) raise in its July 2025 public offering?
What are the terms of BCTX's July 2025 offering warrants?
How will BriaCell use the proceeds from its July 2025 public offering?
Who was the placement agent for BriaCell's July 2025 public offering?
What securities were included in BCTX's July 2025 offering units?
